Find in Library

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterised by progressive loss of memory. In the AD brain, matrix metalloproteinases (MMPs) are involved in the disruption of the blood-brain barrier resulting in a neuroinflammatory response. The objective of our investigation was to assess the association of <i>MMP2</i> rs243866 and rs2285053 polymorphisms with susceptibility to AD, to assess the interaction of <i>MMP2</i> variants with <i>APOE</i> ε4 risk allele, and to evaluate their influence on the age at disease onset and MoCA score. A total of 215 late-onset AD patients and 373 control subjects from Slovakia were genotyped for <i>MMP2</i> rs243866 and rs2285053 polymorphisms. The <i>MMP2</i> association with AD risk and clinical parameters was evaluated by logistic and linear regression analyses. No statistically significant differences in either <i>MMP2</i> rs243866 and rs2285053 allele or genotype frequencies between AD patients and the control group have been observed (<i>p</i> > 0.05). However, the correlation with clinical findings revealed a higher age at disease onset in <i>MMP2</i> rs243866 GG carriers in the dominant model as compared to other <i>MMP2</i> genotype carriers (<i>p</i> = 0.024). Our results suggest that <i>MMP2</i> rs243866 promoter polymorphism may have an impact on the age at AD onset in the patients.